The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer

HIGHLIGHTS

• who: Shih-Chieh Chang from the Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan have published the research work: The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer, in the Journal: Cancers 2011, 3, 2667-2678 of 28/04/2011
• what: In the study , where the EGFR sequencing results of 76 SCLC patients were evaluated, only two patients (2.6%) showed EGFR mutations (exon 19 deletions).
• future: Large prospective studies with a sufficient case number are required . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.